ALLO Stock Forecast 2025-2026
Distance to ALLO Price Targets
ALLO Price Momentum
10 Quality Stocks Worth Considering Now
Researching Allogene (ALLO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ALLO and similar high-potential opportunities.
Latest ALLO Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, ALLO has a bullish consensus with a median price target of $8.50 (ranging from $3.00 to $14.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $1.59, the median forecast implies a 434.6% upside. This outlook is supported by 13 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from John Newman at Canaccord Genuity, projecting a 780.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALLO Analyst Ratings
ALLO Price Target Range
Latest ALLO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALLO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 19, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $8.00 |
| Mar 14, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $10.00 |
| Mar 14, 2025 | Canaccord Genuity | John Newman | Buy | Maintains | $14.00 |
| Mar 14, 2025 | Citizens Capital Markets | Reni Benjamin | Market Outperform | Upgrade | $5.00 |
| Nov 14, 2024 | Piper Sandler | Biren Amin | Overweight | Maintains | $9.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $9.00 |
| Oct 30, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $9.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $9.00 |
| Aug 9, 2024 | Citigroup | Samantha Semenkow | Buy | Maintains | $8.00 |
| Aug 9, 2024 | Truist Securities | Asthika Goonewardene | Buy | Reiterates | $14.00 |
| Aug 8, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $14.00 |
| Aug 8, 2024 | Oppenheimer | Matthew Biegler | Outperform | Assumes | $11.00 |
| May 31, 2024 | Piper Sandler | Biren Amin | Overweight | Initiates | $11.00 |
| May 21, 2024 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $13.00 |
| May 16, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $9.00 |
| May 15, 2024 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $17.00 |
| May 14, 2024 | Stifel | Benjamin Burnett | Hold | Maintains | $4.60 |
| Mar 19, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Mar 15, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $10.00 |
| Feb 27, 2024 | JP Morgan | Brian Cheng | Overweight | Maintains | $8.00 |
Allogene Therapeutics Inc. (ALLO) Competitors
The following stocks are similar to Allogene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Allogene Therapeutics Inc. (ALLO) Financial Data
Allogene Therapeutics Inc. has a market capitalization of $365.01M with a P/E ratio of 0.0x. The company generates $22,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -1,170,372.8% and return on equity of -55.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Allogene Therapeutics Inc. (ALLO) Business Model
About Allogene Therapeutics Inc.
Develops allogeneic CAR T-cell therapies for cancer.
Allogene Therapeutics generates revenue through the development and commercialization of allogeneic CAR T-cell therapies, which are designed to treat various types of cancer. Their innovative approach allows for off-the-shelf treatments, enhancing accessibility and speed of administration compared to traditional therapies that rely on patients' own cells.
The company is a notable player in the biotechnology sector, focusing on both hematologic and solid tumor malignancies. By utilizing advanced gene editing technology, Allogene aims to improve the safety and effectiveness of their therapies, positioning itself as a leader in a transformative approach to cancer treatment and contributing to the growing field of genetically based therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
226
CEO
Dr. David D. Chang M.D., Ph.D.
Country
United States
IPO Year
2018
Website
www.allogene.comAllogene Therapeutics Inc. (ALLO) Latest News & Analysis
ALLO's fourth-quarter earnings exceeded estimates, but the company reported no sales, as it currently has no marketed products.
ALLO's earnings beat estimates, indicating strong financial management despite no sales, which may suggest potential for future product launches and investor confidence.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) will hold its Q4 2024 earnings conference call on March 13, 2025, featuring key executives and analysts from various financial firms.
Allogene's Q4 earnings call reveals insights into financial performance and future strategies, influencing stock valuation and investor sentiment in the biotech sector.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
13 days agoAllogene Therapeutics (Nasdaq: ALLO) reported corporate updates and financial results for Q4 and full year 2024, focusing on its allogeneic CAR T product development for cancer and autoimmune diseases.
Allogene Therapeutics' quarterly and annual financial results impact its stock performance, signaling growth potential or risks in its CAR T development, crucial for investor sentiment.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will report Q4 and full year 2024 financial results on March 13, 2025, followed by a live webcast at 2:00 p.m. PT/5:00 p.m. ET.
Allogene Therapeutics' upcoming financial results and business update may influence stock volatility and investor sentiment, particularly regarding its CAR T product developments.
Allogene Therapeutics expands its collaboration with Foresight Diagnostics to develop a companion diagnostic for identifying LBCL patients eligible for cemacabtagene ansegedleucel treatment.
The collaboration enhances Allogene’s treatment capabilities for LBCL, potentially increasing its market share and driving investor confidence in its growth prospects.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will participate in an investor conference in March 2025, focusing on allogeneic CAR T products for cancer and autoimmune diseases.
Allogene Therapeutics’ participation in an investor conference may signal potential insights on product development and future financial outlook, influencing investor sentiment and stock performance.
Frequently Asked Questions About ALLO Stock
What is Allogene Therapeutics Inc.'s (ALLO) stock forecast for 2025?
Based on our analysis of 22 Wall Street analysts, Allogene Therapeutics Inc. (ALLO) has a median price target of $8.50. The highest price target is $14.00 and the lowest is $3.00.
Is ALLO stock a good investment in 2025?
According to current analyst ratings, ALLO has 13 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALLO stock?
Wall Street analysts predict ALLO stock could reach $8.50 in the next 12 months. This represents a 434.6% increase from the current price of $1.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Allogene Therapeutics Inc.'s business model?
Allogene Therapeutics generates revenue through the development and commercialization of allogeneic CAR T-cell therapies, which are designed to treat various types of cancer. Their innovative approach allows for off-the-shelf treatments, enhancing accessibility and speed of administration compared to traditional therapies that rely on patients' own cells.
What is the highest forecasted price for ALLO Allogene Therapeutics Inc.?
The highest price target for ALLO is $14.00 from John Newman at Canaccord Genuity, which represents a 780.5% increase from the current price of $1.59.
What is the lowest forecasted price for ALLO Allogene Therapeutics Inc.?
The lowest price target for ALLO is $3.00 from at , which represents a 88.7% increase from the current price of $1.59.
What is the overall ALLO consensus from analysts for Allogene Therapeutics Inc.?
The overall analyst consensus for ALLO is bullish. Out of 22 Wall Street analysts, 13 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $8.50.
How accurate are ALLO stock price projections?
Stock price projections, including those for Allogene Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
